Compare TransMedics Group Inc (TMDX) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vertiv Holdings Co — how do they compare? TransMedics Group Inc trades at $74.27 (market cap $2.54B), while Vertiv Holdings Co trades at $305.7 (market cap $112.03B). The key difference: Vertiv Holdings Co is far larger — about 44.1× TransMedics Group Inc's market cap, and Vertiv Holdings Co pays a 0.09% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | VRT | |
|---|---|---|
Market Cap | $2.54B | $112.03B |
Sector | Technology | Technology |
52-Week High | $150.42 | $376.23 |
52-Week Low | $61.99 | $121.82 |
Enterprise Value | $2.94B | $112.80B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Vertiv Holdings (VRT) trades at $291.67, up 0.73% with strong analyst support (94.7% buy ratings) and a $402.92 consensus price target. The stock shows bearish technical signals but maintains robust fundamentals with 14.37% net margins and consistent earnings beats. Recent news highlights AI infrastructure demand driving Vertiv's $15 billion backlog and expansion in Malaysia to support growth.
Outlook remains positive given AI-driven data center investments, though premium valuations (P/E 72.75) and technical weakness near support at $282 pose near-term risks. Earnings on July 29 will be critical for confirming growth trajectory amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
